[go: up one dir, main page]

IS6964A - Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð - Google Patents

Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð

Info

Publication number
IS6964A
IS6964A IS6964A IS6964A IS6964A IS 6964 A IS6964 A IS 6964A IS 6964 A IS6964 A IS 6964A IS 6964 A IS6964 A IS 6964A IS 6964 A IS6964 A IS 6964A
Authority
IS
Iceland
Prior art keywords
ganglioside
tumors
treatment
immunotherapy
formulations
Prior art date
Application number
IS6964A
Other languages
English (en)
Other versions
IS2701B (is
Inventor
Enrique Fern βndez Molina Luis
María V βzquez Lopez Ana
Perez Rodriguez Rolando
Pérez Gonz βlez Alexis
Carr Pérez Adriana
Díaz Rodríguez Yildian
A. Alfonso Fern βndez Mauro
Original Assignee
Centro De Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Inmunologia Molecular filed Critical Centro De Inmunologia Molecular
Publication of IS6964A publication Critical patent/IS6964A/is
Publication of IS2701B publication Critical patent/IS2701B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G01N33/57515—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS6964A 2001-04-06 2003-09-23 Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð IS2701B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000002 WO2002081661A2 (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos

Publications (2)

Publication Number Publication Date
IS6964A true IS6964A (is) 2003-09-23
IS2701B IS2701B (is) 2010-11-15

Family

ID=40291118

Family Applications (2)

Application Number Title Priority Date Filing Date
IS6965A IS6965A (is) 2001-04-06 2003-09-23 Ganglíósíð-tengd raðbrigða mótefni og notkun þeirra í sjúkdómsgreiningu og meðferð á æxlum
IS6964A IS2701B (is) 2001-04-06 2003-09-23 Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS6965A IS6965A (is) 2001-04-06 2003-09-23 Ganglíósíð-tengd raðbrigða mótefni og notkun þeirra í sjúkdómsgreiningu og meðferð á æxlum

Country Status (36)

Country Link
US (3) US20040253233A1 (is)
EP (3) EP1798243B1 (is)
JP (2) JP2004528033A (is)
KR (3) KR100863509B1 (is)
CN (3) CN100349920C (is)
AR (2) AR033123A1 (is)
AT (3) ATE406386T1 (is)
AU (3) AU2002308348B2 (is)
BG (2) BG66304B1 (is)
BR (3) BR0208675A (is)
CA (2) CA2441845C (is)
CU (1) CU23007A1 (is)
CZ (2) CZ296276B6 (is)
DE (2) DE60223547T2 (is)
DK (2) DK1411064T3 (is)
EA (2) EA006936B1 (is)
EC (2) ECSP034787A (is)
ES (2) ES2296986T3 (is)
HR (2) HRP20030806B1 (is)
HU (2) HU228105B1 (is)
IL (2) IL158246A0 (is)
IS (2) IS6965A (is)
MX (2) MXPA03008739A (is)
MY (3) MY145703A (is)
NO (2) NO331533B1 (is)
NZ (2) NZ528598A (is)
PE (1) PE20020972A1 (is)
PL (2) PL208109B1 (is)
PT (2) PT1411064E (is)
SG (1) SG161737A1 (is)
SI (2) SI1384726T1 (is)
SK (2) SK287783B6 (is)
UA (3) UA75393C2 (is)
UY (2) UY27243A1 (is)
WO (2) WO2002081496A2 (is)
ZA (2) ZA200307585B (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
CN103169958A (zh) * 2005-02-04 2013-06-26 萨瓦克公司 存活蛋白肽疫苗
FI20055398A0 (fi) * 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
JP2009505640A (ja) * 2005-08-11 2009-02-12 − ロジャーズ、アルピ マトシアン 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP5465542B2 (ja) * 2008-02-22 2014-04-09 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
HUE029619T4 (en) 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
MX2011010264A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
CA2780713A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
WO2012096994A2 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
PE20150223A1 (es) 2012-06-15 2015-02-11 Pfizer Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
HRP20240939T1 (hr) 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
WO2015157629A2 (en) * 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
MA42428B1 (fr) 2015-06-16 2023-10-31 Hoffmann La Roche Anticorps humanisés et à maturation d'affinité dirigés contre fcrh5 et méthodes d'utilisation
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
JP7126269B2 (ja) 2016-11-30 2022-08-26 メレオ バイオファーマ ５ インコーポレイテッド Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
ES2144440T3 (es) * 1992-08-18 2000-06-16 Centro Inmunologia Molecular Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
DE69428763T2 (de) * 1993-12-09 2002-08-01 Centro De Inmunologia Molecular, Ciudad De La Habana Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
BRPI0208675B1 (pt) 2018-03-13
EP1411064B1 (en) 2007-11-14
KR100863509B1 (ko) 2008-10-15
JP4366080B2 (ja) 2009-11-18
WO2002081661A3 (es) 2003-01-03
BR0208676B1 (pt) 2017-11-14
CN1319991C (zh) 2007-06-06
ZA200307585B (en) 2004-09-16
BG108227A (bg) 2005-04-30
NO20034437D0 (no) 2003-10-03
ES2296986T3 (es) 2008-05-01
US8758753B2 (en) 2014-06-24
MY137078A (en) 2008-12-31
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
IL158246A0 (en) 2004-05-12
IS2701B (is) 2010-11-15
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
EP1411064A2 (en) 2004-04-21
ECSP034788A (es) 2004-01-28
JP2004525953A (ja) 2004-08-26
AR033123A1 (es) 2003-12-03
NO20034436L (no) 2003-12-02
CA2441845C (en) 2011-06-07
KR20080080680A (ko) 2008-09-04
CA2443372A1 (en) 2002-10-17
KR100946168B1 (ko) 2010-03-11
WO2002081496A3 (es) 2004-02-19
EP1798243A2 (en) 2007-06-20
SI1411064T1 (sl) 2008-04-30
ZA200307679B (en) 2005-03-30
MY157372A (en) 2016-06-15
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
HU228105B1 (en) 2012-11-28
CN1535282A (zh) 2004-10-06
EP1384726A2 (en) 2004-01-28
HRP20030806B1 (hr) 2011-11-30
NO20034437L (no) 2003-12-02
ATE477279T1 (de) 2010-08-15
KR20030092048A (ko) 2003-12-03
MXPA03008738A (es) 2003-12-11
PT1411064E (pt) 2008-02-12
SG161737A1 (en) 2010-06-29
EP1384726B1 (en) 2008-08-27
HRP20030805B1 (hr) 2011-11-30
HUP0401695A3 (en) 2012-05-29
AR033122A1 (es) 2003-12-03
SK12162003A3 (sk) 2004-05-04
UY27242A1 (es) 2002-07-31
EA006936B1 (ru) 2006-06-30
DE60228561D1 (de) 2008-10-09
CN101054417B (zh) 2012-07-11
UA86768C2 (ru) 2009-05-25
ES2312610T3 (es) 2009-03-01
HUP0401355A3 (en) 2012-05-29
IL158246A (en) 2010-05-31
DK1411064T3 (da) 2008-03-25
BG66293B1 (en) 2013-02-28
UY27243A1 (es) 2002-09-30
HRP20030806A2 (en) 2005-08-31
HU228106B1 (en) 2012-11-28
SK287783B6 (sk) 2011-09-05
US20100297008A1 (en) 2010-11-25
WO2002081496A2 (es) 2002-10-17
EP1798243B1 (en) 2010-08-11
DK1384726T3 (da) 2008-12-15
DE60223547D1 (de) 2007-12-27
CN100349920C (zh) 2007-11-21
CZ296276B6 (cs) 2006-02-15
MY145703A (en) 2012-03-30
ATE406386T1 (de) 2008-09-15
UA75393C2 (en) 2006-04-17
EP1798243A3 (en) 2007-10-17
BR0208676A (pt) 2008-04-08
CN1507452A (zh) 2004-06-23
CA2441845A1 (en) 2002-10-17
CZ20032668A3 (cs) 2004-07-14
HK1066818A1 (en) 2005-04-01
CN101054417A (zh) 2007-10-17
MXPA03008739A (es) 2003-12-11
US20040253233A1 (en) 2004-12-16
BG66304B1 (bg) 2013-03-29
BR0208675A (pt) 2004-08-03
NO331533B1 (no) 2012-01-23
AU2002308347B2 (en) 2006-09-14
HK1070080A1 (zh) 2005-06-10
DE60223547T2 (de) 2008-09-18
NZ528599A (en) 2005-03-24
HRP20030805A2 (en) 2005-08-31
AU2002308348B2 (en) 2007-11-22
AU2007231687A1 (en) 2007-11-22
SI1384726T1 (sl) 2009-04-30
EA006310B1 (ru) 2005-10-27
IS6965A (is) 2003-09-23
HUP0401695A2 (en) 2006-08-28
PE20020972A1 (es) 2003-01-02
HUP0401355A2 (hu) 2004-10-28
CU23007A1 (es) 2004-12-17
NZ528598A (en) 2005-03-24
CA2443372C (en) 2013-05-28
KR100919617B1 (ko) 2009-09-29
ECSP034787A (es) 2004-01-28
CZ304424B6 (cs) 2014-04-30
PL371770A1 (en) 2005-06-27
EA200301097A1 (ru) 2004-02-26
BG108228A (bg) 2005-04-30
US20050069535A1 (en) 2005-03-31
AU2007231687B2 (en) 2010-09-30
ATE378356T1 (de) 2007-11-15
EA200301098A1 (ru) 2004-04-29
HK1109160A1 (en) 2008-05-30
CZ20032641A3 (cs) 2004-07-14
PT1384726E (pt) 2008-12-05
JP2004528033A (ja) 2004-09-16

Similar Documents

Publication Publication Date Title
IS6964A (is) Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
IL159771A0 (en) Combinations for the treatment of inflammatory disorders
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
IS7202A (is) Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
AU2002308347A1 (en) Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
NO20040482L (no) Fremgangsmåte til fremstilling av tolterodin.
NO20023445D0 (no) Fremgangsmåte for fremstilling av peptider
EP1415655A4 (en) IMMUNOTHERAPY FOR PEOPLE
DK1350521T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
IS7136A (is) Aðferð til meðhöndlunar á svefnleysi á frumstigi
MXPA02006102A (es) Metodo para preparar compuestos bormodifluoroaceticos.
NO20035136D0 (no) Fremgangsmåte til fremstilling av imipenem
AU2002304883A1 (en) Device for the treatment of tumours
MXPA03009210A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE OXABISPIDINAS.
PT1451177E (pt) Derivados substituídos de 2-pirrolidin-2-1l-1h-indole para o tratamento da enxaqueca.
GB2415379B (en) Methyl-ß-orcinolcarboxylate from lichen (everniasrum cirrhatum) for use for the treatment of cancer
DK1395331T3 (da) Anordning til behandling af svulster
DK2105135T3 (da) Farmaceutiske sammensætninger til behandling af cancer